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• Frequency and Clinical Correlates of 
AntHntsrcalated Disk Autoantibodles in Dilated 
Cardiomyopathy 
Alida L.P. Cafodo, Alan J. Haven, Jonathan H. Goldman, Karnran M. Balg, 
Philip J. Keeling, William J. McKenna. Dept of Cardiology, University of 
Padua, Padua, Italy; Dept of CardiolOgical Sciences, St George's Hospital, 
London, United Kingdom 
AntHnteroaialed isk autoantibodies (AIDA) have been reported in patients 
with various autoimmune disorders, but their significance as markers in di- 
lated cardiomyopathy (DCM) is unclear. We assessed AIDA in 179 patients 
with idiopathic (World Health Organization criteria) DCM (137 male, aged 
43 4- 11 years, symptom duration 3,?. ± 43 months, 99 in NYHA 1/11) and 
136 symptom-free relatives (67 male, aged 27 ± 15 years). Controls ware 
132 patients with other cardiac disease (OCD), 62 with heart failure due to 
ischemic heart disease and 200 normais. All patients and disease controls 
underwent heart catheterization and coronary angingraphy; relatives had 
normal clinical and non-invasive valuation. Cardiac antibody test was per- 
formed blindly by indirect Immunofluerascance on human heart; AIDA gave 
a linear staining of the intercalated isks between myocytes. The frequency 
of AIDA was higher both in DCM (18%) and their relatives (11%) than in 
OCD (4%), ischemic heart failure (2%), or in normals ((P,=, p = 0.0001). AIDA 
were more common among DCM patients who were also positive for o~gan- 
specific cardiac antibodies (3~0) than in these positive for cross-reactive 
antibodies (18°/,) Or those who were negative (13%, p = 0.02). AIDA status in 
DCM was associated with NYHA class I/it (p = 0.02) and a higher frequency 
of ve~tdcular ectoplco on Holier (p = 0.02); all other features ware similar in 
AIDA positive and negative patients. The finding of AIDA at increased fre- 
quency in DCM patients and their relatives compared to disease end normal 
controls provides additional evidence for autoimmunity in DCM. It remains 
to be determined whether AIDA are markers related to the development of 
conduction disease or tachyarrhythmia. 
[ '~ '~ Expression of  Fibroblast Growth Faster in the Left 
Ventricle of  Patients With Idiopathic 
Cardlamyopathy 
Yoshifuml Tomita, Chikas Ibukl, Yasuhiro Nagae, Koichi Setsuta, 
Yoshihiko Seine, Kazuo Munahata, Hlroshi Kishlde, Hirokazu Hayakawa. 
Nippon Medical School, Tokyo, Japan 
Experimental studies have demonstrated iverse actions Of fibrololest growth 
factor (FGF) such as cellular pmfiferation and growth, and capillary angtogen- 
esis. To clarify patheghysiologlcal roles of FGF in idiopathic ardiomyopathy, 
LV endomyocardiat biopsy specimens from 24 patients (9 HCM, 12 DCM, 
and 3 hypertensive hypertrophy) and 6 centrals were stained for acidic FGF 
(aFGF) using immunchistochemistry. Average diameter of myecytas, percent 
area of interstitial fibrosis and capillary vessel density in each biopsy spec- 
imen were assessed with morpheme/do methods. In s/tu hybridization was 
carried out for detection of aFGF mRNA. Positive staining of aFGF was ob- 
served In myocytes of biopsy specimen from 15 of 21 (71%) can:liomyopathy 
patients (6 of 9 HCM, 9 of 12 DCM), all hypertensive hypertrophy patients, 
but none of the controls (p < 0.01; cardiornyopathy vs controls). Average 
diameter of myocytas was larger in patients with positive aFGF staining 
than those with negative staining (23.1 ± 6.3 vs 18.3 ± 3.9 pro, p < 0.05). 
Percent area of fibrosis and capillary vassal density were not significantly 
different between two groups, however. Intense expression of aFGF mRNA 
was observed in myocytes from the patients with positive aFGF protein. !n 
conclusion, expression of FGF is significanlly increased in the left ventri- 
cle of eardiomyopathy. Acidic FGF may play an impodant role on myocyte 
hypertrophy. 
[ "9"~ Creatlne Kinase Isoforms as Cireulating Markers of 
Deterioration i Idiopathl© Dilated Cardiomyopathy 
Mojgan Hesse/n-N/a, Jonathan H. Goldman, Philip J. Keeling, William 
J. McKenna, David W. Holt, Department of CaMio/ogical Sciences, St. 
Geerge's Hospital Medical School, London SW17 ORE, UK 
Chronic myocardial damage Is present in a proportion of patients with dilated 
cardiomyopathy (DCM). The prognostic determinants identify patients with 
decreased survival but do not provide a measure of myocardial damage. To 
obtain an objective assessment of myocardial damage In DCM, we measured 
plasma levels of crest/he kinase (CK) activity, its isoanzymes (CK-MM and 
CK-MB activities), and Isoforms (MM3/MM1 and cardiac spesiiio MB2/MB1 
ratios), The cohort consisted of 77 consecutive patients with DGM, aged 49 
± 14 years (range 19--38), 61 male. Patients had been symptomatic for 29 
-v 38 months (Range 0.5-200 months) with 48 in NYHA class 1/11 and 29 in 
class Ill/IV st the time of diagnosis. During median follow-up of 27 months 
from diagnosis (range 0.6--165), 60 patients remained clinically stable and 
27 had detarioroted. A significantly higher proportion of DCM patients had 
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abnormal MB2/MB1 ratio compared to 76 normal volunteers studied (14, 
18°/= vs 1, 1%, p = 0.005). Patients who deteriorated had higher MB2/MB1 
ratio, (1.2,?, ± 0.62 vs 0.85 ± 0.56; p = 0.01). and more frequently had 
abnormal MB2/MB1 ratio (8, 30°/, vs 3, 6%; p = 0.004) and abnormal CKoMM 
(9, 33% vs 6.12%; p = 0.02), than those who remained stable. DCM patients 
wi;.h high CK-MB activity had 3.13-fdid increased odds of sudden death or 
cardiac transplantation (CI 1.53-6.40. p = 0.008). The MB2/MB1 ratio was 
associated with increased left ventdcular dilatation (r = 0.23, p = 0.008). 
Thus, CK measurements, in particular CK-MB isoforms, were found to be 
sensitive markers of myecardial damage in a subset of patients with DCM 
and could be useful in investigating the possibiSty of persistent myocardial 
damage in these patients. 
~ Myocardial  Energetlcs in Dilated Congestive 
Cardiomyopathy 
William H. Devlin, Janet A. Petrusha, Karde Briesmeister, Sunil K. Des, 
Mark R. Starling, Department of Medicine, University of Michigan and VA 
Medical Centers, Ann Arbor, MI 
To define the state of myocardial energetics in patients (pts) with dilated 
congestive cardiomyopathy (DCCM), we studied 6 pts (mean LV ejection 
fraction of 0.27 ± 0.11) at baseline and with dobutamine (5 mcg/kg/min) 
using a micromanometer catheter for LV pressures, radionuciide angiogra- 
phy for LV volumes, and a coronary sinus catheter for myocardial oxygen 
consumption (MVO2) over a range of loading conditions. We calculated 
LV chamber elastance (F_~), total vascular etsstance (Ea), ventrlculo-artsdal 
coupling (E~/Ea), pressure-volume area (PVA), contractile lement efficiency 
I/(MVO2/P/A)], external work (EW), pump efficiency (EW/PVA), and my- 
ecardlal efficiency (EWxHR/MVO2). As anticipated, E~ was tow (0.30±0.13 
mmHg/ml, normal = 1.00 mmHg/ml or mere). Due to impaired LV contractility, 
F,~/Ea was low (0.23 ± 0.12) and EW/PVA was reduced (0.18 4- 0.16). A 
relationship existed between Ees/Ea and EW/PVA (R = 0.96, p < 0.001). 
Contractile lement efficiency was high (41%) due to a flat MVO2/PVA rela- 
tionship [2A5 x 10 -s ml O2/(mmHg/ml), p < 0.0001] along with a low MVO2 
intercept (0.007 ml/min). Dobutamine improved F_~/E a (0.30 ± 0.06) and 
EW/PVA (0.31 ± 0.03). It also increased the MVO2 intercept o 0.02 mVmin; 
but it did not alter the slope. Thus, PVA-indepandent and PVA-dependent 
energy utilization am reduced in pts with DCCM. Dobutamine increased PVA- 
independent, but not PVA-degendent energy utilization, despite improved 
E~/Ea and EW/PVA. Consequently, myocardial efficiency was unaltered. 
These preliminary observations uggest hat beth impaired contractility and 
energy conversion may contribute to reduced energy utilization in pts with 
DCCM. 
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Repeated "Non-lnvasive" Cardiac Output 
Measurements Using an Implanted Right 
Ventriculsr Oxygen Sensor and a I-temodynsmic 
Monitor  in Heart Failure Patients 
Ake Ohlsson, Rolf Nordlander, Hans Astr0m, Barbro Kjetlstr0m, Bdan Lee, 
Mark Claxton, Bob Beck, Frans Ottanheff, Tom Bennett, I.am Ryddn. 
Department of Cardio~, Kamlinska Hospital, Stockholm, Sweden; Heart 
Failure Management, Medtronic Inc., Minneapolis, MN 
Introduction. Continuous ambulatory monitoring of central hemodynamlcs 
using an implantable monitoring system cou~ be of importance for manage- 
ment of patients with severe heart failure. Such system offers furthermore 
an opportunity of repeated "non-invaslve" card~c output measurements ac- 
cording to the Flck pdeotpfe. 
Methods. Five patients, tour with chronic heart failure and one with chronic 
pulmonan/disease ware implanted with a hemodynamic monitoring system 
(HMS) that has the ,same design as an ordirmry pacemaker system. Oxygen 
saturation (02) and pressure in the right ventricle are continuously measured 
and stored. 
The patients underwent supine exercise testing ~3C r,0 watts, 5 miputos) 
~uring cardiac catheterization at 0, 2, 6 and 11 months a,ter implantation, 
Oxygen consumption was measured by ages exchange anaiysar. Simultane- 
ouslY, mixed venous 02 from the HMS and artsdal 02 from a pulse oximeter 
were registered. Cardiac output was calculated from these parameters and 
hemoglobin (Hgb) and the carrying capacity constant for Hgb. The data ware 
presented on line by a computer. For comparison invasive measurements 
ware performed simultaneously. 
